PROSTATE ADENOCARCINOMA

This study tests a new way to treat prostate cancer using a single, high-dose radiation session aimed only at the tumor, not the whole prostate. For early-stage patients, this may be enough to cure the cancer. For higher-risk patients, the single session is followed by standard r…

This study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

This study tests a personalized approach to radiation therapy for men whose prostate cancer has returned after surgery. Instead of giving everyone the same treatment, doctors will adjust the plan based on how well the cancer responds to initial radiation. Those who respond well m…

This study tests a program designed to help men with prostate cancer manage their heart health while undergoing hormone therapy (ADT). The program involves two counseling sessions with a nurse or physician assistant to educate about cardiovascular risks and how to reduce them. Re…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…

This study compares two treatments for low-to-intermediate risk prostate cancer: a new robotic surgery that removes part of the prostate through a single small incision, and high-intensity focused ultrasound (HIFU) that uses sound waves to destroy cancer cells. About 276 men will…

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…

This Phase III trial is testing whether using PET scans to guide treatment can help men whose prostate cancer has returned after surgery. For those without signs of spread outside the pelvis, researchers are adding a drug called apalutamide (plus other hormones) to standard radia…

This study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…

This study tests whether giving radiation to the para-aortic lymph nodes (located in the abdomen) can better control prostate cancer that has returned in a limited number of spots. Men with hormone-sensitive prostate cancer and up to five lesions seen on a PSMA PET/CT scan will r…

This phase II trial is testing whether adding two hormone-blocking drugs, relugolix and enzalutamide, to standard radiation therapy can better control very-high-risk prostate cancer. About 50 men will receive the combination for 18 months. The main goal is to see if it lowers the…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab, alone or combined with etrumadenant or tocilizumab, can boost immune cell activity in prostate tumors before surgical removal. About 68 men with localized prostate cancer will receive treatment before radi…

This study is testing a new way to give radiation for high-risk prostate cancer that has not spread. One hundred men will receive a shorter, stronger radiation boost to the prostate along with standard pelvic radiation. The goal is to see if this approach is safe and does not cau…

This study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…

This study tests a next-generation radiation therapy (SABR) for men with low to high-risk prostate cancer. The goal is to see if this advanced technique can control the cancer while reducing long-term side effects like urinary and bowel problems. About 136 participants will recei…

This trial tests a type of internal radiation called high-dose-rate brachytherapy for men with early-stage prostate cancer. The goal is to see if focusing radiation only on the tumor can control the cancer while causing fewer urinary and sexual problems than standard treatments. …

This phase 2 trial tests whether a daily supplement called urolithin A can lower oxidative stress in prostate tumors. Ninety men with prostate cancer will take either urolithin A or a placebo for 3 to 6 weeks before their prostate removal surgery. The main goal is to see if the s…

This study tests whether eating 2 ounces of walnuts daily for 4-10 weeks can slow prostate cancer growth in 50 men scheduled for prostate removal. Participants are randomly assigned to add walnuts to their usual diet or stick with their normal eating habits. Researchers will meas…

This study tests whether a special 5-day-per-month diet that mimics fasting can improve how well standard prostate cancer treatments work. 138 men with advanced prostate cancer will either follow this diet or eat normally for 6 months. Researchers will measure PSA levels and meta…

This study tests a personalized approach to radiation therapy for high-risk prostate cancer. Using special PET scans that highlight cancer cells, doctors will adjust the timing and dose of radiation to each patient's tumor. The goal is to improve treatment effectiveness while red…

This study is testing whether adding a short, high-dose radiation boost to standard radiation therapy can safely improve treatment for men with unfavorable localized prostate cancer. The boost is delivered non-invasively using stereotactic body radiotherapy (SBRT), similar to a n…

This Phase 2 trial is testing whether a single dose of Lu-177-PSMA-617 (Pluvicto), a radioactive drug that targets prostate cancer cells, can shrink or eliminate high-risk prostate tumors before surgery. About 54 men with aggressive prostate cancer (Gleason score 8 or higher) wil…

This trial tests whether giving radiation every other day (5 sessions total) is as safe as the standard daily schedule (20 sessions) for men who have had prostate cancer surgery. The study involves 204 participants across multiple centers. The main goal is to see if the shorter s…

This study tests a new type of radiation therapy for men with prostate cancer that has spread to lymph nodes in the abdomen or pelvis. The treatment uses daily CT scans to adjust the radiation beam precisely to the tumor and nearby at-risk areas. The goal is to control the cancer…

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug throug…

This study is for men whose prostate cancer has come back in a few spots after radiation, but is still hormone-sensitive. Researchers want to see if adding a 12-month course of hormone therapy (ELIGARD) to targeted treatments like radiation or surgery helps keep the cancer from g…

This study tests whether using MRI scans to guide radiation can lower the dose to healthy parts of the prostate while targeting cancer spots. The goal is to reduce bowel-related side effects without losing cancer control. About 60 men with intermediate- or high-risk prostate canc…

This study tests whether adding a drug called relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 people whose cancer has not responded to standard treatments will take the study drugs for 24 weeks, then h…

This early-stage study tests a small implant called Enolen that delivers the drug enzalutamide directly into the prostate. The goal is to see if it is safe and how much drug reaches the tumor. About 56 men with prostate cancer who are already scheduled for prostate removal surger…

This study is testing whether a single, high-dose radiotherapy session can safely control prostate cancer in men with intermediate or high-risk disease. About 58 participants will receive one focused radiation dose to the tumor, guided by MRI and imaging. The goal is to see if th…

This early-phase study tests a new way to deliver radiation implants (brachytherapy) for men with localized prostate cancer. By using advanced imaging (PET/CT and ultrasound) to map only the aggressive tumor areas, doctors hope to target the cancer while leaving healthy tissue un…

This study tests whether adding a special hormone therapy (bipolar androgen therapy) to a targeted radiation drug (radium-223) can slow the growth of prostate cancer that has spread to bones and stopped responding to standard hormone treatments. About 47 men with this advanced ca…

This early-phase trial is testing whether a combination of two hormone-blocking drugs (darolutamide and relugolix) can safely shrink high-risk prostate tumors before they are surgically removed. About 30 men with aggressive prostate cancer will take the drugs for a short time bef…

This study tests a single, very high dose of radiation (17 Gy) to the prostate area in men whose prostate cancer has come back after surgery. The goal is to see if this precise, one-time treatment can control the cancer while reducing side effects. Fifty men will be enrolled, and…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This study is for men with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. It tests whether giving the chemotherapy drug carboplatin before surgery can shrink tumors more effectively. About 44 participants will receive carboplatin, and researchers will…

This study tests whether a shorter, more intense radiation treatment (5 sessions) is better than the standard 20-session approach for men with intermediate- or high-risk prostate cancer that hasn't spread. The goal is to improve cancer control while keeping side effects low. Abou…

This phase 2 trial tests whether taking abiraterone 250 mg with food and prednisone can lower testosterone to castration levels in prostate cancer patients, without using standard hormone-blocking injections or surgery. The study enrolls 60 men with prostate cancer who need hormo…

This study is for men with prostate cancer that has returned after surgery and radiation, but only shows up in a few places on a special PET scan. The goal is to treat those specific spots with targeted therapy, which may help control the cancer and delay the need for long-term h…

This phase 2 trial is testing whether giving fewer hormone therapy drugs (abiraterone acetate and GnRH analogs) along with radiation can work as well as longer treatment for high-risk prostate cancer that has spread a little. The goal is to reduce side effects while still control…

This study is testing a new type of radiation therapy called adaptive SBRT for men with intermediate- or favorable high-risk prostate cancer. The goal is to see if it can safely deliver a higher dose of radiation directly to the tumor while avoiding nearby organs, which may reduc…

This study tests whether a very short course of radiation (5 days) is as safe and effective as a longer course (2-3 weeks) for men with localized prostate cancer. All participants also receive a brachytherapy boost. The main goal is to compare side effects and quality of life ove…

This phase 3 study is testing whether adding a short course of hormone therapy (androgen suppression) to image-guided radiation therapy helps men with intermediate-risk prostate cancer. About 192 men will receive either radiation alone or radiation plus hormone therapy. The goal …

This study at Mayo Clinic is testing whether a special ultrasound technique called vibroelastography can better assess erectile function recovery in men after prostate cancer surgery. The technique measures tissue stiffness, which may indicate scarring. Ten men with low-risk pros…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, aggressive prostate cancer who are planning to have their…

This study is testing whether a special PET scan using flotufolastat F 18 can detect prostate cancer that has come back after surgery, even when PSA levels are very low (0.20 ng/mL or less). Researchers will scan 50 men with a history of prostate cancer and a rising PSA after pro…

This study tests a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that doctors might miss. About 180 people with known or suspected prostate cancer will get an MRI and then a targeted biopsy. Researchers will compare the software's a…

This Phase 3 trial is testing whether a radioactive tracer called [18F]PSMA-1007 can improve PET/CT scans for men with newly diagnosed high-risk or very-high-risk prostate cancer. The goal is to see if it can more accurately detect cancer that has spread to pelvic lymph nodes. Ab…

This study tests whether a short course of hormone therapy (relugolix) can make PSMA PET/CT scans better at finding prostate cancer that has spread to lymph nodes. About 30 men with high-risk prostate cancer will get the hormone drug for 5, 10, or 15 days before their scan. The g…

This study is testing whether adding a special PET scan (using a radioactive tracer called flotufolastat F18) to the standard MRI can better find aggressive prostate cancer in men who are currently on active surveillance. About 120 men with low- or favorable intermediate-risk pro…

This study compares a personalized biopsy method that uses fewer needle cores to the standard approach for diagnosing prostate cancer. Researchers will enroll 330 men with suspected prostate cancer and randomly assign them to either the personalized or standard biopsy. The goal i…

This study aims to see if a special PET scan (68Ga-PSMA-11) is better than standard MRI at finding prostate tumors in people who have just been diagnosed and haven't started treatment. About 100 participants will receive both scans before surgery, and the results will be checked …

This study is testing a new radioactive tracer called 68Ga-P16-093 for PET scans to see how well it finds prostate cancer tumors compared to standard MRI scans. About 50 people with newly diagnosed, untreated prostate cancer will receive both scans before their prostate removal s…

This study is for men with low- to intermediate-risk prostate cancer. It compares giving a lower radiation dose to some parts of the prostate versus the same dose to the whole prostate. The goal is to see if the lower dose reduces short-term urinary side effects. About 54 people …

This study tests whether personalized nutrition and exercise plans can reduce frailty and improve body composition in prostate cancer survivors who are on hormone therapy (ADT). Fifty participants will receive diet advice, exercise coaching, and educational sessions. Researchers …

This study is testing whether giving a lower dose of radiation in just two sessions can reduce side effects for men with intermediate-risk prostate cancer. All participants will be treated on a special MRI-guided machine (MR-Linac) that adapts the radiation daily. The main goal i…

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…

This study tests if using a special dye (ICG) during robot-assisted prostate removal helps preserve nerves and improve recovery of bladder control and sexual function. About 400 men with prostate cancer will take part. The goal is to see if the dye leads to better outcomes 12 mon…

This trial compares two types of radiation therapy for low-risk prostate cancer: SBRT (a precise, high-dose external beam treatment) and low-dose rate brachytherapy (implanting radioactive seeds). The goal is to see which causes fewer urinary and bowel side effects and leads to a…

This study compares two types of radiation for prostate cancer: one that targets only the tumor and one that treats the whole prostate. The goal is to see if the focused approach causes fewer short-term side effects like bladder or bowel problems. About 150 men with intermediate-…

This study tests whether giving a lower radiation dose to healthy parts of the prostate, while keeping a high dose to visible tumors, can reduce bowel and urinary side effects in men with low or intermediate-risk prostate cancer. Participants will receive two sessions of MRI-guid…

This study tests whether a digital exercise program with online group sessions can help prostate cancer patients on hormone therapy exercise more regularly. 160 participants will either get standard care or standard care plus the digital program. Adherence is tracked with a weara…

This study tests a precise radiation technique called neurovascular-sparing SBRT for men with prostate cancer. The goal is to see if customizing each treatment session based on MRI images can better protect the nerves and blood vessels needed for erections, compared to standard r…

This study tests a technique called 'Spot Delete' during pencil beam scanning proton therapy for low- and intermediate-risk prostate cancer. The goal is to reduce side effects like diarrhea, rectal bleeding, and urinary problems by preventing proton beams from stopping in sensiti…

This trial compares two different schedules of MRI-guided radiation for men with low or favorable intermediate risk prostate cancer. One group gets the standard five sessions, the other gets just two sessions. The goal is to see if the shorter course can maintain cancer control w…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study is a registry that collects information from 1,000 men with prostate cancer who receive focal therapy using high-intensity focused ultrasound (HIFU) or irreversible electroporation (IRE). No new treatment is given—researchers simply record patient details, disease feat…

This study follows 837 men with high-risk prostate cancer who choose either robot-assisted surgery or radiation therapy (with or without hormone therapy). Researchers will compare quality of life, side effects, and cancer control over time. The goal is to help patients and doctor…

This study is testing a special MRI scan that uses a substance called hyperpolarized pyruvate to see how well it can monitor prostate cancer in patients who are not receiving treatment. About 60 men with low- to intermediate-risk prostate cancer will be scanned to measure how the…

This study compares two hormone-lowering drugs, Orgovyx and Eligard, in men with prostate cancer who are also getting radiation therapy. The goal is to see which drug has less impact on heart function and overall heart health. About 70 participants will undergo heart tests, exerc…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This study is looking for substances in urine that could help predict how well prostate cancer treatments work. Researchers will collect urine samples from 360 men with prostate cancer who are receiving standard treatments like surgery, radiation, chemotherapy, or hormone therapy…

This study looks at whether providing cancer care at home is a good option for Black men with advanced prostate cancer. Researchers want to see if this approach can reduce healthcare disparities and improve quality of life. Participants will fill out questionnaires about their pr…

This study checks if a new PET-CT scanner (RefleXion X1) can see prostate cancer tumors as well as the standard scanner does. About 25 men with prostate cancer who are already getting a standard PET scan will get an extra scan on the new machine. The goal is to see if the new sca…

This study is creating an artificial intelligence (AI) model that uses MRI scans and tissue samples to predict whether high-risk prostate cancer has spread to nearby lymph nodes. The goal is to help doctors make better treatment decisions without needing extra invasive tests. Abo…

This study looks at whether a genetic test can help decide which men with prostate cancer can safely have a less invasive treatment called focal therapy, which targets only the tumor instead of the whole prostate. Researchers will enroll 130 men and use the test to classify their…

This study looks at whether certain substances in the blood can help doctors predict how prostate cancer patients will respond to their treatment. Researchers will collect blood samples from 600 men at different stages of prostate cancer and analyze them for biomarkers. The goal …

This study is collecting blood samples from 24 men with high-risk localized prostate cancer before they have their prostate removed. Researchers will use a highly sensitive test to look for tiny bits of tumor DNA floating in the blood. The goal is to see if this DNA can help pred…

This study looks at how hormonal therapy changes PSMA levels in men with prostate cancer, both in early and advanced stages. Researchers will use PSMA PET scans at different times after starting therapy to see when the scan is most accurate for staging the cancer. The goal is to …

This study follows 120 men with advanced prostate cancer to see if markers in their blood can predict how well they respond to hormone therapy. Researchers will collect blood samples and compare markers between those who respond well and those who don't. The goal is to develop a …